Alteogen said Wednesday that it promoted ALT-P7, an antibody-drug conjugate (ADC) breast and stomach cancer treatment candidate, which uses its NexMab antibody technology, at the 9th ADC in San Diego, Calif.
The four-day event featured 650 ADC experts from 220 companies, including development companies such as Abbvie, Astellas, Takeda, and Daiichi-Sankyo, and global pharmaceutical companies that want to license out the drug, including Pfizer, Novartis, BMS and Genentech.
“Our antibody-drug conjugation (ADC) breast cancer treatment is a very simple and highly yieldable method of drug conjugation compared to other company's site-specific conjugation techniques,” said Jung Kyung-hoon, Alteogen’s head of business development division.
It is a second-generation ADC breast cancer treatment that is progressing smoothly in phase I clinical trials for patients and has already demonstrated high safety and efficacy in previous non-clinical trials, including monkeys, Jung added.
Through the presentation, Alteogen has proved its superior ADC technology to global pharmaceutical companies seeking to develop ADC drugs, he said.
Alteogen, which develops antibody-drug biobetters, is conducting phase 1 clinical phase in Korea for a second-generation ADC breast cancer and stomach cancer drug.
According to the company, its drug is superior regarding side effects and efficacy compared to Roche’s Kadcyla. The U.S. Food and Drug Administration designated the drug as an orphan drug for stomach cancer in August.